You just read:

Inclusion of data on treatment discontinuation in the Tasigna® product monograph approved by Health Canada for CML patients who achieve a sustained molecular response(i)

News provided by

Novartis Pharmaceuticals Canada Inc.

Nov 13, 2018, 07:00 ET